Cellectis
CLLS
#8359
Rank
โ‚น27.61 B
Marketcap
โ‚น274.23
Share price
1.43%
Change (1 day)
25.87%
Change (1 year)

Revenue for Cellectis (CLLS)

Revenue in 2026 (TTM): โ‚น6.03 Billion

According to Cellectis's latest financial reports the company's current revenue (TTM ) is โ‚น6.57 Billion. In 2025 the company made a revenue of โ‚น6.54 Billion an increase over the revenue in the year 2024 that were of โ‚น3.56 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Cellectis from 2015 to 2026

Annual revenue

Year Revenue Change
2026 (TTM) โ‚น6.03 B-7.89%
2025 โ‚น6.54 B83.91%
2024 โ‚น3.56 B5565.07%
2023 โ‚น62.85 M-96.01%
2022 โ‚น1.57 B-63.02%
2021 โ‚น4.26 B-20.25%
2020 โ‚น5.34 B396.29%
2019 โ‚น1.07 B19.8%
2018 โ‚น0.89 B-43.94%
2017 โ‚น1.60 B-44.4%
2016 โ‚น2.88 B-20.57%
2015 โ‚น3.63 B

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
Regeneron Pharmaceuticals
REGN
โ‚น1.440 T 21,818.03%๐Ÿ‡บ๐Ÿ‡ธ USA
uniQure
QURE
โ‚น1.74 B-73.42%๐Ÿ‡ณ๐Ÿ‡ฑ Netherlands
Novavax
NVAX
โ‚น57.58 B 776.07%๐Ÿ‡บ๐Ÿ‡ธ USA
Flexion Therapeutics
FLXN
โ‚น9.69 B 47.50%๐Ÿ‡บ๐Ÿ‡ธ USA